Toremifene Citrate 60mg/ml @ 30ml

Toremifene Citrate – SERM for Metastatic Breast Cancer 

Toremifene Citrate is a second‑generation selective estrogen receptor modulator (SERM) , structurally related to tamoxifen. It acts as an estrogen antagonist in breast tissue, effectively blocking estrogen‑dependent tumor growth. Toremifene is clinically indicated for the treatment of metastatic breast cancer in postmenopausal women with estrogen receptor‑positive (ER+) disease. Compared to tamoxifen, Toremifene offers a comparable efficacy profile with a potentially lower incidence of certain genotoxic effects. It is also studied for its tissue‑specific activity in bone and lipid metabolism.

Key Applications:

• ER+ metastatic breast cancer research

• SERM comparative efficacy studies

• Estrogen receptor antagonism models